logo
Two rebounding stocks for the long run

Two rebounding stocks for the long run

While many investors are fond of bowing down to market fluctuations as gospel, the mostly unspoken truth is that rebounding stocks, as well as those in precipitous downfalls, require supporting facts for these fluctuations to qualify as rational.
In other words, a stock's spike up or down speaks to its underlying company's valuation only if there's evidence for it.
In its absence, the market's bipolar tendencies might be offering you a discount to build a position, or overvaluation to make a profitable exit.
In its presence, you're the beneficiary of a data-driven investment thesis and can begin to hash out expectations in terms of time horizon and expected return.
In the newest edition of Stockhouse's Weekly Market Movers, I'll analyze a pair of rebounding mining stocks supported by operations that seem to have what it takes to ramp up momentum moving forward. Atlas Salt
Our first rebounding stock, Atlas Salt, market capitalization C$47.67 million, is developing the Great Atlantic salt project in Newfoundland, which is positioned to be Canada's next salt mine.
The feasibility-stage project holds an estimated post-tax net present value of C$553 million, offering the potential for a 34-year operating life extracting about 84.5 million tons of salt in probable reserves, in addition to resources of 368 million tons indicated and 827 million tons inferred.
According to Atlas Salt's investor presentation for June 2025, the price of U.S. rock salt imports has more than doubled since 2000 to over US$65 per ton, with North America importing about a quarter of its salt annually, granting the company plenty of room to capitalize on the ongoing trend of onshoring critical material supply chains.
At total capital costs of C$1.1 billion, with a payback period of only 5 years, Great Atlantic is rapidly advancing towards production through permitting and an updated feasibility study to further validate project economics for investors and offtake partners. An initial non-binding memorandum of understanding with Scotwood Industries targets distribution of 1.25 to 1.50 million tons of salt products per year.
Atlas Salt stock (TSXV:SALT), in turn, has bounced back by 36.11 per cent from its year-to-date low, largely driven by the upcoming feasibility study and the hiring of a new CEO and CFO that bring ample experience with major miners and financial institutions.
I think a handful of priorities in 2025 are likely to keep pushing the stock up and to the right, including advancing regulatory compliance, geotechnical and hydrological site evaluation, potential production expansion, as well as the conversion of a pipeline of strategic partnerships into initial revenue.
Nolan Peterson, Atlas Salt's CEO, spoke with Stockhouse's Lyndsay Malchuk about the new feasibility study, which is expected in Q3 2025. Watch the interview here. Kootenay Silver
Our second rebounding stock, Kootenay Silver, market capitalization C$74.89 million, is a mineral explorer that controls one of the largest junior silver portfolios in Mexico, which Visual Capitalist ranks as the world's top silver-producing country. The company's portfolio is highlighted by: Its flagship Columba project, housing a maiden resource estimated at 54.1 million ounces in silver resources inferred.
The Promontorio-La Negra and La Cigarra properties, representing a collective 214.2 million ounces of silver equivalent measured and indicated and 54.9 million ounces of silver equivalent inferred.
At prices as of June 20, these properties are sitting on more than US$11.6 billion in silver in the ground combined, a sum on a completely different plane of existence versus the company's micro market capitalization.
And with Kootenay stock up by only 2.56 per cent year-over-year, heavily trailing silver's 20 per cent gain, you wouldn't exactly intuit the company's multi-billion-dollar potential, or the fact that its operations are well-equipped to close this valuation-resource gap in a significant way. Key drivers behind this thesis include: A leadership team with success developing early-stage mining projects into acquisition-worthy targets.
A C$17.4 million bought-deal offering with Research Capital expected to close on June 25 to further advance Columba, with funds going towards an ongoing 50,000-metre drilling program that has yielded numerous intercepts in the thousands of grams of silver per ton (g/t) with numerous high-grade targets still to be explored.
An abundance of targets on its secondary properties waiting in the wings to add fuel to a bid for a stock price re-rating.
An approximately 5 per cent investment from Canadian Mining Hall of Fame member Eric Sprott doesn't hurt either, in terms of differentiating the company from competitors when it comes to future capital raises.
Over the past month-and-a-half, the market has been showing early signs of recognizing the value proposition we're laying out, with Kootenay stock (TSXV:KTN) adding more than 30 per cent over the period propelled by Columba's maiden resource, as well as a highlight intercept of 7,360 g/t silver and 30.57 per cent lead-zinc announced in early May.
With exploration capital nearly in hand, look for positive news flow over the summer to continue fostering this upward trend and building awareness of Kootenay's major status among junior silver miners.
James McDonald, Kootenay Silver's president and CEO, joined Coreena Robertson to comment on Columba's maiden resource estimate. Watch the interview here.
Thanks for reading! I'll see you next week for a new edition of Stockhouse's Weekly Market Movers. Here's the most recent article, in case you missed it.
Join the discussion: Find out what everybody's saying about these rebounding stocks on the Atlas Salt Inc. and Kootenay Silver Inc. Bullboards and check out Stockhouse's stock forums and message boards.
This is sponsored content issued on behalf of Atlas Salt Inc. and Kootenay Silver Inc., please see full disclaimer here.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment

Cision Canada

time30 minutes ago

  • Cision Canada

Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /CNW/ -- USA News Group News Commentary – Federal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fill the gap, with oncology ventures securing hundreds of millions in funding so far in 2025. The Senate's recent restoration of $15 million for the Pancreatic Cancer Research Program (PCARP) was a win, yet its earlier elimination underscored the fragility of public support. Against this backdrop, investors are zeroing in on companies with standout science, solid pipelines, and clear regulatory strategies, including Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), Fate Therapeutics, Inc. (NASDAQ: FATE), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), and Nektar Therapeutics (NASDAQ: NKTR). Global Market Insights estimates the global oncology market at US$345.1 billion in 2025 and forecasts it will climb to US$866.1 billion by 2034, growing at a robust 10.8% CAGR. The U.S. alone is expected to contribute $377.1 billion to that total. Vision Research Reports projects an even larger figure for the global cancer drug sector, predicting it will surpass US$900 billion in sales by 2034. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has officially entered the most critical phase of its development journey—pursuing a potential registration-enabling trial in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) for its flagship asset, pelareorep. In its latest Q2 2025 report, the company confirmed it has begun formal discussions with the U.S. Food and Drug Administration (FDA) aimed at finalizing a pivotal study design, with trial start-up activities expected to begin as early as Q4 2025. For investors and potential partners, this represents a clear transition from promising clinical data to potential regulatory approval in one of medicine's most challenging cancer types. "We have turned the corner from proof-of-concept studies and will be sprinting toward regulatory clarity for the remainder of the year," said Jared Kelly, CEO of Oncolytics. "As we shore up our intellectual property, get a clear registration path for pelareorep, and allow our GOBLET data to mature, we will establish our position as the only platform immunotherapy in gastrointestinal tumors." The strategic focus on mPDAC reflects both compelling clinical results and a significant market opportunity. Pelareorep is a systemically delivered oncolytic virus designed to convert immunologically "cold" tumors—those typically invisible to the immune system—into "hot" tumors that can respond to immunotherapy. In first-line pancreatic cancer studies, pelareorep-based regimens have demonstrated a notable 21.9% two-year overall survival rate, compared to a 9.2% historical benchmark for standard chemotherapy alone. Even more compelling, when pelareorep was combined with chemotherapy and a checkpoint inhibitor, researchers recorded a 62% objective response rate—particularly significant given that checkpoint inhibitors are not currently approved for use in this indication. These results stem from pelareorep's dual mechanism: it both replicates within cancer cells and activates the body's immune response against tumors. "This robust data set, amassed from several studies in cancers that have historically resisted immunotherapeutic approaches, provides definitive validation of pelareorep's immune-mediated mechanism of action," said Dr. Thomas Heineman, Chief Medical Officer of Oncolytics. "We observed tumor biopsy-confirmed virus replication, immune cell activation, and the recruitment of cytotoxic T cells into the TME—all consistent with the durable responses observed in patients with metastatic PDAC and HR+/HER2- breast cancer who were treated with pelareorep." Translational data from the GOBLET and AWARE-1 studies demonstrate how pelareorep transforms the tumor microenvironment, increasing PD-L1 expression, heightening interferon signaling, and mobilizing tumor-infiltrating lymphocytes in the blood—changes that correlate with tumor size reduction. This mechanistic validation, combined with survival data from over 1,100 patients across multiple studies, has solidified the company's decision to prioritize this indication. Oncolytics' execution-focused strategy is being led by Jared Kelly and Andrew Aromando, who both played key roles in Ambrx Biopharma's US$2 billion acquisition by Johnson & Johnson. Kelly was appointed CEO earlier this year, while Aromando recently joined as Chief Business Officer. In line with their focus on capital efficiency, the company has terminated its At-the-Market and Equity Line of Credit facilities, citing sufficient resources to advance key milestones without near-term shareholder dilution. Regulatory advantages are already in place to accelerate development. Pelareorep holds Fast Track and Orphan Drug designations for pancreatic cancer from the FDA, meaning the agency has already recognized both the drug's potential and the serious unmet need in this patient population. These statuses streamline review processes and enhance the program's attractiveness to potential pharmaceutical partners. The context underscores the opportunity: pancreatic cancer remains one of the deadliest common cancers, with a five-year survival rate of less than 14%. Unlike other cancers where immunotherapies have transformed treatment, mPDAC has largely resisted immunotherapeutic approaches—making pelareorep's immune-activating mechanism particularly promising for this underserved patient population. Back in July, Oncolytics hosted a key opinion leader event featuring gastrointestinal cancer experts who reviewed survival outcomes for patients and biomarker validation. The expert panel reinforced the view that pelareorep's mechanism of activating innate and adaptive immune responses is both biologically sound and commercially relevant for first-line mPDAC treatment. With this latest milestone, Oncolytics is entering a phase where FDA feedback will shape both clinical plans and potential commercial partnerships. If the agency accepts the company's proposed trial framework centered on an overall survival endpoint, the resulting study could provide definitive proof of pelareorep's market potential in mPDAC. The company expects to provide an updated clinical timeline in Q3 2025, with trial start-up activities potentially beginning as early as Q4 2025. With compelling survival data, regulatory designations in place, and an experienced leadership team driving execution, Oncolytics is positioning pelareorep for a pivotal test in one of oncology's most challenging and underserved markets. In other recent industry developments and happenings in the market include: Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) reported strong Q2 2025 results with $60 million in total product revenue, driven primarily by its breakthrough melanoma therapy Amtagvi, which treated over 100 patients in the second quarter. "Growth for Amtagvi and Proleukin will continue in the second half of 2025 as existing ATC growth continues and large community practices begin treating patients," said Frederick Vogt, Ph.D., J.D., Interim President and CEO of Iovance. "We expect our first ex-U.S. regulatory approval imminently and remain on track to provide updates on our clinical programs." The company's tumor-infiltrating lymphocyte (TIL) therapy—which uses a patient's own immune cells to fight cancer—generated $54.1 million in revenue and represents the first FDA -approved T-cell therapy for solid tumors, offering new hope for advanced melanoma patients who have tried other treatments without success. With expanded clinical trials planned for lung cancer and endometrial cancer, plus international approvals expected in Canada and other markets, Iovance is positioned to bring its innovative cancer treatment to patients worldwide. Fate Therapeutics, Inc. (NASDAQ: FATE) recently announced promising clinical progress for its off-the-shelf CAR T-cell therapy FT819, which showed lasting responses in lupus patients and received FDA clearance to begin trials for a solid tumor program targeting MICA/B proteins. While primarily focused on autoimmune diseases, the company's next-generation FT836 CAR T-cell therapy represents a significant advancement in cancer treatment as it's designed to target solid tumors without requiring harsh conditioning chemotherapy, potentially making the treatment safer and more accessible. "Building on this momentum, we are also working closely with the FDA under our RMAT designation with the goal of commencing our registrational study for FT819 in SLE and LN in 2026," said Bob Valamehr, Ph.D., MBA, President and CEO of Fate Therapeutics. "Additionally, we continue to strengthen our broader pipeline programs with an extended partnership with Ono Pharmaceuticals, and advancements in bringing our next-generation, off-the-shelf CAR T cells with Sword and Shield™ technology toward the clinic." The company's stem cell-based platform continues to advance multiple programs, including partnerships for HER2-positive solid tumors, positioning Fate as a leader in developing ready-made cancer cell therapies. Inovio Pharmaceuticals, Inc. (NASDAQ: INO) remains on track to submit its application for INO-3107 in the second half of 2025, targeting Recurrent Respiratory Papillomatosis (RRP), a rare cancer-related condition caused by HPV that affects the airways. The company's DNA medicine platform represents a novel approach to treating HPV-related diseases and cancers, with INO-3107 showing significant clinical benefit by reducing the need for repeated surgeries in RRP patients from an average of 4.1 procedures annually to just 0.9 procedures. "We believe that INO-3107 could become the preferred treatment option for Recurrent Respiratory Papillomatosis (RRP) patients and their physicians—a treatment option with the potential to change the trajectory of this disease," said Dr. Jacqueline Shea, President and CEO of INOVIO. "I look forward to building on the significant progress of this past quarter and providing updates as we work toward a potential approval date in mid-2026." Beyond RRP, Inovio's technology platform is designed to treat various HPV-related cancers and other tumors by teaching the body's immune system to recognize and fight cancer cells. With breakthrough therapy designation from the FDA and plans for a trial involving 100 patients, INO-3107 could become the first DNA-based therapy approved for treating this serious cancer-related condition. Nektar Therapeutics (NASDAQ: NKTR) reported impressive Phase 2b data for rezpegaldesleukin in treating moderate to severe atopic dermatitis, with the company positioning this immune system regulator as a first-in-class treatment for autoimmune diseases. While primarily focused on autoimmune conditions, Nektar's pipeline includes NKTR-255, a treatment designed to boost the immune system's ability to fight cancer, which is being tested in multiple ongoing clinical trials with various partners. "As a first-in-class, T regulatory cell biologic, rezpegaldesleukin is poised to become an important novel mechanism to treat millions of patients with autoimmune disorders," said Howard W. Robin, President and CEO of Nektar. "Finally, we are making significant progress on advancing preclinical studies with a new bispecific antibody, NKTR-0166, which combines the TNFR2 epitope with a validated antibody target." The company's technology platform creates novel treatments that could potentially address both autoimmune diseases and cancer by enhancing the immune system's cancer-fighting abilities. With additional data expected from hair loss trials in December 2025 and continued development of next-generation programs, Nektar is advancing a unique approach to immune system therapy that could benefit millions of patients with serious diseases. CONTACT: USA NEWS GROUP [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Cathie Wood's ARK ETFs See Record Investor Rush
Cathie Wood's ARK ETFs See Record Investor Rush

Globe and Mail

timean hour ago

  • Globe and Mail

Cathie Wood's ARK ETFs See Record Investor Rush

After years of outflows and underperformance, Cathie Wood's ARK ETFs are burning hot, pulling in massive capital. The firm's 13 U.S.-listed ETFs have gathered $3.7 billion in AUM over the past week, led by record-breaking single-day hauls. The flagship ARK Innovation ETF ARKK led the charge, raking in a record $1.1 billion on Monday and an even larger $1.4 billion on Tuesday, which marks the biggest single-day inflows since 2021. ARK defines ''disruptive innovation'' as the introduction of a technologically enabled new product or service that potentially changes the way the world works. This was followed by ARK Next Generation Internet ETF ARKW, which saw its largest-ever single-day haul, with $349 million on Tuesday. The massive surge in inflows has flipped ARK's year-to-date tally from deep red to $2.6 billion in net inflows for 2025. ARKK accounted for $2.8 billion of last week's surge, boosting its AUM to $8.6 billion, or 40% of ARK's total. ARKW took in $707 million, bringing its asset base to $2.8 billion. A Stunning Comeback From April Lows ARKK has nearly doubled in three months from an April low of near $40, riding strong gains in holdings like Coinbase COIN, Roblox RBLX, Shopify SHOP, Palantir PLTR, Robinhood HOOD and Circle IPO. ARKW mirrored this rebound, now trading just 13% below its 2021 peak, compared to ARKK's 50% gap (read: ETFs to Ride on Palantir's First Billion-Dollar Quarter Revenues). Return of Retail Fervor & 'Disruptive' Innovation The inflow surge is fueled in part by renewed retail enthusiasm for 'meme' and high-volatility 'cult' stocks, echoing the pandemic-era mania that initially catapulted ARK into the limelight. ARK's active approach, which had struggled post-2021 due to ill-timed exits (like missing NVIDIA's AI surge), now appears better aligned with current innovation trends, contributing to renewed confidence. Reallocations by Cathie Wood Cathie Wood, the high-profile CEO of Ark Investment Management, remains especially bullish on the transformative power of emerging technologies. "During the current turbulent transition in the United States, she believes consumers and businesses will accelerate the shift toward innovation platforms, including artificial intelligence, robotics, energy storage, blockchain, and multiomics sequencing.' As such, Cathie Wood is sticking to her trademark playbook — buying into high-growth tech names when volatility sends prices tumbling. This week, both ARKK and ARKW snapped up more than 725,000 shares of ad-tech leader Trade Desk TTD, after the stock plunged 38.6% on Friday following a disappointing earnings report, soft guidance and the surprise departure of its CFO. This is ARK's first Trade Desk buy since February. With this purchase, TTD is now the 27th-largest holding in ARKK and the 29th-largest in ARKW, worth about $85 million and $28 million, respectively. Wood also purchased about $19 million of Block shares across its ETFs, including ARKK and ARKW. This reflects a better entry point as the stock hit a three-week low, signaling renewed conviction in fintech. The firm also bought approximately 1.7 million shares of Bullish BLSH across ARKK and ARKW, reinforcing its bet on digital asset innovation. These transactions underscore ARK's active, opportunistic strategy in high-growth sectors from fintech to crypto platforms. Let's take a closer look at the fundamentals of ARKK & ARKW. ARKK ARK Innovation ETF is an actively managed fund investing in companies that benefit from the development of new products or services, technological improvements and advancements in scientific research related to the areas of DNA technologies and genomic revolution, automation, robotics, energy storage, artificial intelligence, next-generation Internet and Fintech innovation. In total, the fund holds 44 securities in its basket and charges 75 bps in fees per year from investors. It trades in an average daily volume of 12 million shares. ARKW ARK Next Generation Internet ETF is an actively managed fund focusing on companies expected to benefit from the shift in technology infrastructure to the cloud, enabling mobile, new and local services that rely on or benefit from the increased use of shared technology, infrastructure and services, Internet-based products and services, new payment methods, big data, the Internet of Things, and social distribution and media. The fund holds 46 stocks in its basket. ARK Next Generation Internet ETF charges 82 bps in annual fees and trades in an average daily volume of 372,000 shares (read: 5 American ETFs Witnessing Gains Ahead of Independence Day). Boost Your Portfolio with Our Top ETF Insights Don't miss out on this valuable resource. It's free! Get it now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Shopify Inc. (SHOP): Free Stock Analysis Report ARK Next Generation Internet ETF (ARKW): ETF Research Reports ARK Innovation ETF (ARKK): ETF Research Reports The Trade Desk (TTD): Free Stock Analysis Report Palantir Technologies Inc. (PLTR): Free Stock Analysis Report Roblox Corporation (RBLX): Free Stock Analysis Report Coinbase Global, Inc. (COIN): Free Stock Analysis Report Robinhood Markets, Inc. (HOOD): Free Stock Analysis Report This article originally published on Zacks Investment Research (

AI firm Cohere raises US$500 million, giving business US$6.8 billion valuation
AI firm Cohere raises US$500 million, giving business US$6.8 billion valuation

Winnipeg Free Press

time2 hours ago

  • Winnipeg Free Press

AI firm Cohere raises US$500 million, giving business US$6.8 billion valuation

TORONTO – Cohere says it's raised US$500 million, giving the Canadian artificial intelligence firm a US$6.8 billion valuation. The funding round was led by Radical Ventures and Inovia Capital, with additional cash from AMD Ventures, Nvidia, PSP Investments, Salesforce Ventures and the Healthcare of Ontario Pension Plan. Cohere says the money will accelerate the Toronto-based company's efforts to build agentic AI products. It says its AI aims to free people from tedious tasks, giving them more time for more interesting and challenging work. In addition to the funding, Cohere announced Joelle Pineau, who was previously Meta's vice-president of AI research, will become the company's chief AI officer. Wednesdays What's next in arts, life and pop culture. Francois Chadwick, who has worked at Uber and KPMG, will become Cohere's chief financial officer. This report by The Canadian Press was first published Aug. 14, 2025.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store